MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen
receptors (CARs) T cell therapy for relapsed and refractory ovarian cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Zhejiang University
Collaborators:
Hrain Biotechnology Co., Ltd. Hrain Biotechnology Co.,Ltd. Second Affiliated Hospital, School of Medicine, Zhejiang University